EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Profiling EGFR , c‐ MET , and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancer

Yanan Yang, Huiyu Li, Shiwei Xiao, Mengxia Jiao, De Wu, Chunxia Ao, Yanggeling Zhang, Siyuan Yan, Shaomei Sun, Chen Yang, Renhong Tang, Xiyuan Wang und 1 weitere

The Journal of Pathology: Clinical Research · 2026

DOI: 10.1002/2056-4538.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2026. Verfasst von Yanan Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins c-met, ErbB Receptors, B7 Antigens. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 2020 Jingjian·Tongshu Microsatellite Instability Research Fund Project, Health commission of Hubei Province scientific research project, Research Projects of Biomedical Center of Hubei Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR), cellular mesenchymal‐epithelial transition factor (c‐MET), and B7 homolog 3 (B7H3) are important targets for antibody‐based drug development in colorectal cancer (CRC). To overcome the limitations of single‐target antibody therapies – such as limited efficacy, widespread resistance, narrow patient populations, and treatment‐related toxicities – various bispecific antibodies or antibody–drug conjugate (ADCs) targeting two targets are being extensively validated in clinical settings. A deeper understanding of their expression profiles and co‐expression patterns of actionable therapeutic targets may guide more effective treatment strategies. We evaluated the immunohistochemical expression of B7H3, c‐MET, and EGFR in a cohort of 193 CRC patients. Among which, B7H3 exhibited the highest positivity rate (80.83%) in CRC tissues, followed by c‐MET (77.20%) and EGFR (47.15%). The positive rates of B7H3 showed no significant differences across patient gender, age, TNM stage, differentiation grade, or tumor site. In contrast, the c‐MET positivity rate was elevated in patients with stage I–II disease, and the expression of EGFR was significantly higher in female patients than in male patients. Concurrent assessment of the three targets in metastatic lesions revealed that B7H3 expression levels were comparable between primary and metastatic tumors, whereas c‐MET expression was significantly higher in primary lesions. Co‐expression analysis indicated that the group with the highest patient coverage was the B7H3/c‐MET dual‐positive group, followed by the B7H3/EGFR, and c‐MET/EGFR combinations, and the proportion of patients with at least one positive target exceeded 80%. Finally, mRNA profile from TIMER database reveals that CD276 and MET expression in CRC tumor tissues were higher than those in the majority of normal tissues. Therefore, utilizing B7H3/c‐MET combination therapies that integrate intracellular signaling inhibition with immune checkpoint modulation could potentially extend therapeutic benefits to a wider range of CRC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins c-metErbB ReceptorsB7 AntigensImmunoconjugatesBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedImmunohistochemistryAdultAged, 80 and over

Stichwörter der Autor:innen

B7H3EGFRIHCantibody–drug conjugatebiomarkercolorectal cancerc‐METdigital pathology

Substanzen

Proto-Oncogene Proteins c-metErbB ReceptorsCD276 protein, humanB7 AntigensEGFR protein, humanImmunoconjugatesBiomarkers, TumorMET protein, human

Autor:innen und Institutionen

  • Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
  • Hubei Provincial Clinical Research Center for Colorectal Cancer, Wuhan, PR China.
  • Wuhan Clinical Research Center for Colorectal Cancer, Wuhan, PR China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, PR China.

Förderung

  • 2020 Jingjian·Tongshu Microsatellite Instability Research Fund Project
  • Health commission of Hubei Province scientific research project
  • Research Projects of Biomedical Center of Hubei Cancer Hospital

Zitieren

APA

Yang, Y., Li, H., Xiao, S., Jiao, M., Wu, Ao, C., Zhang, Y., Yan, S., Sun, S., Yang, C., Tang, R., Wang, X., & Yue, J. (2026). Profiling EGFR , c‐ MET , and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancer. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70118

Vancouver

Yang Y, Li H, Xiao S, Jiao M, Wu, Ao C, et al. Profiling EGFR , c‐ MET , and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancer. The Journal of Pathology: Clinical Research. 2026. doi:10.1002/2056-4538.70118

BibTeX
@article{Yang2026,
  author = {Yang, Yanan and Li, Huiyu and Xiao, Shiwei and Jiao, Mengxia and Wu, De and Ao, Chunxia and Zhang, Yanggeling and Yan, Siyuan and Sun, Shaomei and Yang, Chen and Tang, Renhong and Wang, Xiyuan and Yue, Junqiu},
  title = {Profiling EGFR , c‐ MET , and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancer},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2026},
  doi = {10.1002/2056-4538.70118}
}
Kostenlos starten →